Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study

Breast Cancer Research and Treatment

Volumn 51, Issue 2, 1998, Pages 169-181

  Geyer Jr , Charles E ^a   Green, Stephanie J ^b   Moinpour, Carol M ^b   O'Sullivan, Janet ^b   Goodwin, Donna K ^c   Canfield, Vikki A ^d   Meyers, Frederick J ^e   Osborne, C Kent ^f   Martino, Silvana ^g  

^a Joe Arrington Cancer Center   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g The Breast Center Inc   (United States)

Author keywords

Metastatic breast cancer; Paclitaxel; Symptom reduction

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ARTICLE; BREAST METASTASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL DISEASES; HEART DISEASES; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; NEUROMUSCULAR DISEASES; PACLITAXEL; PAIN MEASUREMENT; PALLIATIVE CARE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 7844225510     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006094403153     Document Type: Article

References (34)

1. O'Shaughnessy JA, Wittes RE, Burke G, et al.: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9: 2225-2231, 1991
2. Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases (ed 2). Lippincott, Philadelphia, PA, 1991, pp 628-630
3. Holmes FA, Walters RS, Theriault RL, et al.: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991
4. Reichman B, Seidman A, Crown J, et al.: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial therapy for metastatic breast cancer. J Clin Oncol 10: 1943-1951, 1993
5. Rowinsky EK, Donehower RC: Paclitaxel (Taxol®). N Engl J Med 332: 1004-1014, 1995
6. Swenerton K, Eisenhauer E, Huinink WT, et al.: Taxol in relapsed ovarian cancer: High vs low dose and short vs long infusion. Proc Am Soc Clin Oncol 12: 256, 1993 (abst 810)
7. Nabholtz JM, Gelmon K, Bontenbal M, et al.: Randomized trial of two doses of taxol in metastatic breast cancer: An interim analysis. Proc Am Soc Clin Oncol 12: 60, 1993 (abst 42)
8. Postma TJ, Liefting AJM, Heimans JJ, et al.: Neurotoxicity in patients with breast cancer and ovarian cancer treated with taxol. Proc Am Soc Clin Oncol 12: 64, 1993, abstract 56
9. McCorkle R, Young K: Development of symptom distress scale. Cancer Nurs 1: 373-378, 1978
10. McCorkle R, Benoliel JQ: Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease. Soc Sci Med 17: 431-438, 1983
11. McCorkle R, Benoliel JQ, Donaldson G, Goodell B: Evaluation of cancer management. Final report of project NU 01001. Supported by the Division of Nursing. Bureau of Health Professions, Health Resources and Services Administration, U.S. Public Health Service, 1986
12. McCorkle R, Benoliel JQ, Donaldson G, et al.: A randomized clinical trial of home nursing care for lung cancer patients. Cancer 64: 1375-1382, 1989
13. McCorkle R: The measurement of symptom distress. Semin Oncol Nurs 3: 248-256, 1987
14. Young KJ, Longman AJ: Quality of life and persons with melanoma: A pilot study. Cancer Nurs 6: 219-225, 1983
15. Cohen J: Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale NJ: Lawrence Erlbaum Associates, Publishers, 1988
16. Degner LF, Sloan J: Symptom distress in newly diagnosed cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Management 10: 423-431, 1995
17. Northouse LL, Laten D, Reddy P: Adjustment of women and their husbands to recurrent breast cancer. Res Nurs Health 18: 515-524, 1995
18. Pasacreta JV: Depressive phenomena, physical symptom distress and functional status among women with breast cancer. Nurs Res (in press)
19. Samarel N, Fawcett J, Tuonan L: The effects of coaching in breast cancer support groups: A pilot study. Oncol Nurs Forum 20: 795-798, 1993
20. Green SJ, Weiss G: SWOG standard response, criteria end-point definition and toxicity criteria. IND 10: 239-253, 1992
21. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 16: 297-334, 1951
22. Howell A, Mackintosh J, Jones M, et al.: The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Clin Oncol 24: 1567-1572, 1988
23. Gianni L, Munzone E, Capri G, et al.: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169-1174, 1995
24. Nabholtz JM, Gelmon K, Bontenbal M, et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1866, 1996
25. Seidman AD, Tiersten A, Hudis C, et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581, 1995
26. Weiner H, Berry D, Duggan D, et al.: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342. Proc Am Soc Clin Oncol 17: 101a, 1998, abstract 388
27. Peretz T, Sulkes A, Chollet P, et al.: A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31A (suppl 5): S75, 1995, abstract 345
28. Mamounas T, Brown A, Smith R, et al.: Effect of taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3-to 24-hr infusion of high-dose taxol. Proc Am Soc Clin Oncol 17: 101a, 1998, abstract 389
29. Holmes FA, Valero V, Buzdar AV, et al.: Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer. The long and short of it. Proc Am Soc Clin Oncol 17: 110a, 1998, abstract 426
30. Asbury R, Chang A, Burroughs L, et al.: Weekly moderate dose paclitaxel in advanced breast cancer. Proc Am Soc Clin Oncol 17: 127a, 1998, abstract 486
31. Breier S, Lebedinsky C, Ayiviri C, et al.: Long-term weekly paclitaxel in metastatic breast cancer. A phase II trial in pretreated patients. Proc Am Soc Clin Oncol 17: 192a, 1998, abstract 740
32. Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 334: 835-840, 1996
33. Seidman AD, Portenoy R, Yao TJ, et al.: Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87: 1316-1322, 1995
34. Moinpour CM, Feigl P, Metch B, et al.: Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 85: 485-495, 1989